Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Protagonist Therapeutics, Inc
Bear Case (25th pct.)
-86.6% vs price
Base Case (Median)
-83.6% vs price
Bull Case (75th pct.)
-77.1% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $23.13 | -83.6% | Medium (25%) |
| Graham Number | $14.70 | -89.6% | Medium (40%) |
| EV/FCF | $41.40 | -70.6% | Medium (20%) |
Based on 3 out of 7 methods, PTGX appears overvalued at the current price of $141.00. The base case fair value of $23.13 implies 83.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.